Agenus (AGEN) Misses Q3 Earnings and Revenue Estimates

Core Insights - Agenus reported quarterly earnings of $1.94 per share, missing the Zacks Consensus Estimate of $2.63 per share, compared to a loss of $3.17 per share a year ago, indicating an earnings surprise of -26.24% [1] - The company posted revenues of $30.2 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 71.95%, but showing an increase from year-ago revenues of $25.11 million [2] - Agenus shares have increased approximately 45.3% since the beginning of the year, outperforming the S&P 500's gain of 14.4% [3] Earnings Outlook - The future performance of Agenus stock will largely depend on management's commentary during the earnings call and the company's earnings outlook [4][5] - The current consensus EPS estimate for the upcoming quarter is -$0.21 on revenues of $72.55 million, and for the current fiscal year, it is $0.61 on revenues of $229.95 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Agenus belongs, is currently ranked in the top 36% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]